Evidence map›Paper›PMID 35654388›Full record

ArticleDrug discovery today2022

A global bibliometric and visualized analysis of bacteria-mediated cancer therapy.

Jiawei Wang, Mohammed Maniruzzaman

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug discovery today, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Review
  8. Tumor-targeting bioluminescent bacteria forEngineering microbiology · 2025
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Bibliometric analysis of intestinal microbiota and lung diseases.Frontiers in cellular and infection microbiology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jiawei WangPharmaceutical Engineering and 3D Printing (PharmE3D) Lab, Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, Austin, TX 78712, USA.
Mohammed ManiruzzamanPharmaceutical Engineering and 3D Printing (PharmE3D) Lab, Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, Austin, TX 78712, USA. Electronic address: m.maniruzzaman@austin.utexas.edu.

Funding

A Novel First-in-class 3D Printing Technology for Advanced Manufacturing of Complex Vaccine Formulations against Influenza and Emerging Infectious DiseasesR01FD007456 · FDA · UNIVERSITY OF TEXAS AT AUSTIN · PI MANIRUZZAMAN, MOHAMMED · 2021 to 2023
$1.5M
FDA HHS R01 FD007456
6 · The paper itself

Abstract

Bacteriotherapy has proved to be a powerful tool to fight against cancer. Herein, we used VOSviewer, CiteSpace, and Python to perform the first global bibliometric analysis of the literature from 2012 to 2021 on bacteria-mediated cancer therapy. Based on the results, East Asia and North America contributed the most publications to this research area. Additionally, the keyword analysis indicated that immunotherapy and nanoparticle (NP)-based drug delivery systems have long been popular topics in cancer bacteriotherapy, whereas the gut microbiota and probiotics are emerging research hotspots. This study provides crucial insights into the historical development of bacteria-mediated cancer therapy from 2012 to 2021, which will be helpful for scientists to conduct further investigation into this promising field.

Indexed as

Biomedical ResearchGastrointestinal MicrobiomeNeoplasmsBacteriaBibliometricsHumansBacteriaBibliometric analysisCancerCancer bacteriotherapyImmunotherapy

Identifiers

PMID35654388
PMCPMC9530009

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.